Compare Invesco Ltd. (IVZ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Invesco (IVZ) trades at $30.50, up 0.39% on the day, with a mixed technical outlook showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $281.7 million for 2025 despite revenue growth to $6.38 billion, with profitability metrics like ROE at -2.97% indicating challenges. Recent news highlights the expansion of its QQQ ETF suite and a dividend declaration, while analyst consensus remains cautiously optimistic with a $33.71 price target.

The outlook for IVZ hinges on reversing negative earnings trends and capitalizing on ETF growth initiatives. Key opportunities include strong asset under management growth and product innovation, but risks persist from competitive pressures and market volatility. Investors should weigh the potential for operational improvement against ongoing profitability concerns.

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.